Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction.
Heart failure (HF) is an important global health problem with great socioeconomic burden. Outcomes remain sub-optimal. Endothelium-cardiomyocyte interactions play essential roles in cardiovascular homeostasis, and deranged endothelium-related signalling pathways have been implicated in the pathophysiology of HF. In particular, disturbances in nitric oxide (NO)-mediated pathway and neuregulin-mediated pathway have been shown to contribute to the development of HF. These signalling pathways hold the potential as pathophysiological targets for new HF therapies, and may aid in patient selection for future HF trials.
National University Health System, Singapore.
Shir Lynn
SL
Lim
National University Health System, Singapore.
Carolyn S P
CS
Lam
Laboratory of Physiopharmacology (Building T2), University of Antwerp, Universiteitsplein 1, Antwerp 2610, Belgium.
Vincent F M
VF
Segers
Laboratory of Physiopharmacology (Building T2), University of Antwerp, Universiteitsplein 1, Antwerp 2610, Belgium gilles.dekeulenaer@uantwerpen.be dirk.brutsaert@skynet.be.
Dirk L
DL
Brutsaert
Laboratory of Physiopharmacology (Building T2), University of Antwerp, Universiteitsplein 1, Antwerp 2610, Belgium gilles.dekeulenaer@uantwerpen.be dirk.brutsaert@skynet.be.
Gilles W
GW
De Keulenaer
Endothelium-cardiomyocyte interactions; Heart failure; Neuregulin-mediated pathway; Nitric-oxide mediated pathway; Therapy